Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a malignant tumor with an extremely poor prognosis. Among radically operated patients in high-volume centers, five-year survival rates are as low as 4%-34%, with a median survival ranging between 17 and 27 months. 1 Subsequent second primary malignant neoplasm (SMN) is a term used to describe a new primary cancer that occurs in a patient who has been diagnosed and treated for cancer in the past, months or years after the original primary cancer. SMNs are a major cause of mortality and serious morbidity among cancer survivors who have been
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lovecek et al successfully cured of their first cancer. Their etiologies are multiple and may relate to the role of primary cancer treatment (mainly radiotherapy and chemotherapy), unhealthy lifestyle behaviors, germline and somatic mutations, aging, and most likely a combination of any of these factors. 2, 3 Because of the unfavorable prognosis, very few long-term PDAC survivors will develop SMN. 2, 3 Consequently, there are very few reports about SMNs in PDAC survivors and their prognosis, and there is no information on the genetic background of these patients. [2] [3] [4] [5] [6] [7] [8] [9] The aim of the present study was to identify and describe SMNs in long-term PDAC survivors with regard to their potential genetic background. This is the first study describing the genetic background of long-term PDAC survivors with SMNs.
Patients and methods Patients
This retrospective study involved 118 Caucasian patients with PDAC, who had undergone a curative-intent surgery between 2006 and 2011 at the University Hospital, Olomouc, Czech Republic.
The inclusion criteria for further SMN analysis included a curative-intent surgical treatment, histologic diagnosis of PDAC independently confirmed by two experienced pathologists, at least a five-year survival period after surgery, and postresection follow-up comprising biochemical tumor marker monitoring (CA 19-9, CEA, and CA 125) every 3 months and imaging (computed tomography [CT] or positron emission tomography [PET]/CT) scans performed every 6-12 months or in the case of CA 19-9 elevation.
The clinical data, including age, gender, date of diagnosis, pTNM stage, 10 the histologic type and grade of the tumor, lymphatic, vascular, and perineural invasion, the therapy administered and follow-up, were obtained from medical records. The main clinical characteristics of the whole group are summarized in Table 1 . The retrospective study was approved by the Institutional Review Board of the University Hospital in Olomouc, and all living patients gave their informed written consent to participation in the study and the genetic analysis. The study was conducted in accordance with the Declaration of Helsinki.
The principal objective of this study was the identification of SMNs in this cohort of patients. The criteria used for the definition of SMN were derived from Waren and Gates, including a histologic confirmation of the second primary malignancy, anatomical separations of both tumors or recurrence exclusion, and a second tumor diagnosis >6 months after the diagnosis of the first tumor. 2 The SMNs in the studied cohort were diagnosed by physical examination, endoscopy, and/or diagnostic imaging (CT/PET-CT) and were histologically verified.
next-generation sequencing analysis
Blood was collected during diagnostic procedures using tubes with K 3 EDTA anticoagulant, and DNA was isolated from lymphocytes using the phenol/chloroform extraction method described by Sugimura.
11
A custom-designed CZECANCA panel (SeqCap EZ choice; Nimblegen/Roche) for the germline-targeted nextgeneration sequencing (NGS) analysis of cancer-predisposition and candidate genes was used as described previously. 12 In brief, the panel targets 219 selected genes with a known predisposition to hereditary cancer syndromes (including breast, ovarian, colorectal, pancreatic, gastric, endometrial, kidney, prostate, and skin cancers) and other genes that code for proteins involved in the DNA repair and/or DNA damage response with uncertain clinical relevance. A sequencing 
Bioinformatics analysis
The NGS data were processed according to the in-house bioinformatics pipeline as described recently. 12 In brief, SAM files were generated from FASTQ files using Novoalign v2.08.03 and transformed into BAM files using Picard tools v1.129. The VCF files prepared by GATK were annotated by ANNOVAR. 13 Medium-size indel identification was based on the method of soft-clipped bases using Pindel software, and copy number variation (CNV) analysis was performed using CNV kit. During variant filtration, we excluded low-quality variants (sequence quality <30) and common variants with allelic frequencies >0.01 in ESP6500 and 1,000 genomes databases, respectively. We also excluded variants present >2× in a national database of genotypes that included 507 noncancer controls (data not shown). Nonsense, frameshift, and consensus dinucleotide splice site variants (±1/2) in known predisposition genes were classified as pathogenic or likely pathogenic. Missense variants, silent variants, inframe indels, and other intronic variants were considered only when reaching a CADD score >2 and gerp >0 and classified according to the ClinVar and/or VarSome database. Prioritized variants were further analyzed by three prediction tools (SIFT, PolyPhen-2, and Mutation Analyzer). Variants predicted to be damaging by at least two programs were considered potentially deleterious.
Results
Patients and treatment
Twenty-two patients (19.1%) with histopathologically verified PDAC survived for >5 years since the primary PDAC diagnosis (long-term survivors) and matched the inclusion criteria for this retrospective study. The median follow-up was 6.2 years (range 5-11 years). Long-term PDAC survivors were further screened for the development of SMNs.
Overall, six patients (5.1% of all radically resected PDAC patients) developed SMNs. The SMN rate among long-term survivors was 27% (N=6/22). The mean age of the long-term PDAC survivors at the time of PDAC diagnosis was 61.7±7.8 years (range 44-75 years). The subgroup of patients with SMNs consisted of five males and only one female; the mean age was 66.7±7.4 years (range 51-75 years) at the time of PDAC diagnosis. None of these patients received neoadjuvant chemotherapy. One patient was treated with chemotherapy based on 5-fluorouracil (300 mg/m 2 /day) concomitant to radiotherapy (50.4 Gy in 5.5 weeks) in the adjuvant setting, and the other five patients were treated with six 4-week cycles of gemcitabine (1000 mg/m 2 at days 1, 8, and 22). Overall, of the long-term PDAC survivors in the present cohort, around 40% of patients who received gemcitabine postoperatively developed subsequent malignant neoplasms. The clinical and pathologic data of the patients with SMN are summarized in Table 2 .
Timing and patterns of subsequent secondary malignant neoplasms
The median time to SMN was 52.5 months (range 8.8-87.1 months; Table 2 ). The SMNs observed included two cases of rectal cancer, and one case each of prostate cancer, malignant melanoma, breast cancer, and urinary bladder cancer. Four of these patients underwent a curative surgery for the SMN. The patient with urinary bladder cancer underwent a radical cystectomy 63 months after PDAC resection. The patient with malignant melanoma underwent a radical excision 45.4 months after PDAC resection, and the patient with breast cancer underwent mastectomy 8.8 months after PDAC resection. All these patients are still alive with no recurrence of primary or secondary malignancy (6.3-8.9 years following the primary surgery of PDAC). One patient with rectal cancer died of postoperative complications from rectal surgery 64 months after the PDAC surgery. A second patient with rectal cancer died of cardiovascular comorbidities 62 months after the PDAC surgery without a specific therapy.
Prostate cancer with bone metastases was diagnosed in one patient 87.1 months after the primary PDAC resection and the patient was treated with hormonal therapy.
In summary, none of these patients died as a result of the PDAC.
genetic analysis
A targeted NGS analysis covering 219 PDAC and other cancer susceptibility genes (Table 3) was performed in 20 patients both with and without SMNs (DNA samples from the two deceased patients with rectal cancer were not available).
Deleterious germline mutations were identified in 4 out of 20 NGS-analyzed long-term survivors (20%; Table 4 pathogenic mutation in 16 long-term PDAC survivors without SMN had a positive family cancer history. A patient with RAD51D splice-site mutation c.345+2T> G had a mother with gastric cancer and a patient with two mutations (nonsense variant in MLH1: c.390C>G and frame-shift variant in ATM: c.3849delA) had a father with a colorectal cancer and a father's mother with brain tumor. The remaining patient with the CHEK2 c.1100delC mutation had no personal or family cancer history. Subsequently, we identified several alterations with unknown impact on protein function. Fourteen variants in ten patients were predicted to be damaging by at least three prediction programs (Table 5) .
Discussion
This report demonstrates a relatively high incidence of SMNs in five-year survivors of PDAC. The incidence of SMNs is generally 2%-10% and the prevalence is 6.6%-9%, accounting for about 16% of overall cancer incidence.
2,3,5 So far, very few publications have reported an analysis of second primary extrapancreatic malignancies following PDAC, probably because of the poor prognosis of these patients.
2,6-9 A large population-based study calculated the incidence of SMNs diagnosed after the diagnosis of PDAC to be lower when compared to other cancers (around 1.3%). 8, 14 The latest report of the Czech National Cancer Registry shows a primary PDAC incidence of about 84% and a second primary PDAC (PDAC as the second primary tumor) incidence of about 16%. The incidence of synchronous PDAC and other malignancies is 5% of total PDAC patient incidence and the incidence of SMNs following PDAC is <1% of the total. 15 These rates were confirmed by the study reported by Hackert et al. 16 The unexpectedly high number of SMNs (5%) in the present cohort of resected PDAC patients may be primarily explained by the comprehensive follow-up focusing not only on PDAC recurrence, but also on SMNs. Moreover, among long-term PDAC survivors, we identified SMNs in 27% of patients, indicating that the apparently limited number of SMNs in PDAC reported so far may be largely due to the poor prognosis. Previously published reports on long-term PDAC survivors show prevalences of SMNs ranging between 0% and 20%. 6, 7 Nevertheless, this retrospective analysis may indicate that the development of SMNs in PDAC survivors may be more frequent than has been acknowledged in previous reports.
Improved medical options including anticancer therapy and treatment individualization lead to the prolongation of survival. This is evident in survivors of various primary 17 The same trend has also been confirmed in the Czech population. 18 A higher age at the time of the primary PDAC diagnosis was the only remarkable difference between five-year survivors with SMNs and those without SMNs. The incidence of cancer increases with age, and, consequently, older survivors have a higher risk of SMNs than younger survivors. All patients with a manifestation of SMN received adjuvant chemotherapy consisting of antimetabolites gemcitabine or 5-fluorouracil. Although patients who undergo chemotherapy are generally considered to be at a higher risk of SMN, an increased risk of SMNs after the use of these antimetabolites has not been reported to date.
Therefore, it seems that a higher age at the time of the PDAC diagnosis and a long-term survival after a surgical and chemotherapy treatment may be regarded as risk factors for SMNs, and that such patients should be diagnostically followed.
The NGS analysis revealed five clearly pathogenic variants in four patients from the long-term PDAC survivors subgroup (25%). This frequency was higher than for the other group of 96 unselected PDAC patients, 19 which was 13.5% identified with a panel of 22 genes, but we are aware of the small number of patients analyzed in our study. A recent study by Yurgelun et al 20 identified 28 carriers of germline pathogenic or likely pathogenic mutations in double-strand DNA damage repair genes in 289 patients (9.7%) with resected PDAC. Interestingly, the authors demonstrated that the germline mutations carriers had superior overall survival (HR 0.54; P = 0.05). This indicates that mutations in cancerpredisposing genes increase the risk of prognostically beneficial PDAC; therefore, it might be expected that an increased proportion of mutation carriers should also be found among the long-term PDAC survivors. Unfortunately, the genetic aberrations discovered do not currently seem to be of any clinical relevance with regard to potential therapeutic options.
Considering the small number of long-term survivors, the frequency of pathogenic variants in the group of patients who developed SMNs (25%) and in the group who did not (19%) was comparable. These results suggest that SMN development may be due to a combined effect of variants with low penetrance or may be caused by a combination of genetic and/or nongenetic risk factors. On the other hand, the presence of germline mutations did not dramatically influence risk and prognosis of SMN.
The patient with PDAC at 70 years old and subsequent breast cancer at 71 was identified to harbor a pathogenic missense CHEK2 variant (c.349A>G, p.Arg117Gly). Numerous studies and meta-analyses have shown that mutations in the CHEK2 gene are clearly associated with increased breast cancer risk and also with the development of other solid or hematologic tumors. 21 We failed to find a significant association of CHEK2 germline variants with unselected PDAC cases in our previous study; however, only selected portions of CHEK2 coding sequence were analyzed. 22 Since then, germline CHEK2 mutations have been identified in several studies in patients with PDAC; 19, 20, 23, 24 however, a consensual evaluation of CHEK2 germline variants in PDAC remains to be established.
In a subgroup of 16 long-term PDAC survivors without SMN development, we identified 2 PDAC patients with pathogenic variants in cancer predisposition genes and a positive family history. MLH1 is a Lynch syndrome predisposition gene 25 and can explain the colorectal cancer in the patient's father. RAD51D is an ovarian cancer predisposition gene, 26 but was never associated with gastric cancer. These data indicate that germline mutations in cancer predisposition genes are associated with a wider range of phenotypes than previously suggested.
The evaluation of potentially pathogenic missense germline variants in candidate genes requires further analysis in larger groups of PDAC patients, as well as functional studies, because in silico predictions are suitable for variant prioritization for such analyses, but are not devoted to final variant classification.
The present study, therefore, poses new questions regarding the role of genetic alterations in the development of PDAC and subsequent SMNs in patients, and regarding the modification of the clinical course of the disease. The variants identified in the present study must be verified by further investigations, also in regard to the functional impact. However, this is the first study of genetic alterations in SMNs in PDAC patients and the largest epidemiologic retrospective analysis of SMNs after PDAC treatment in Central Europe.
Conclusion
In our cohort, 27% of five-year PDAC survivors went on to develop SMNs. An intensive follow-up can identify the second primary neoplasms early, at a curable stage. SMN risk factors include a longer survival and a higher age at the time of PDAC diagnosis. Genetic analysis has confirmed the role of pathogenic mutations in pancreatic and other cancers' predisposition genes in long-term surviving PDAC patients; nevertheless, the frequency did not differ in the subgroups with and without SMN development. If the performance status of these patients allows and a second primary tumor 
Publish your work in this journal
Submit your manuscript here: https://www.dovepress.com/cancer-management-and-research-journal Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.
Dovepress
609
second neoplasms after pancreatic cancer has a favorable prognosis, subsequent surgery should be performed.
